Pharmaxis’ first small molecule inhibitor of LOXL2 (lysyl oxidase like 2), an enzyme that promotes fibrosis in the lungs of idiopathic pulmonary fibrosis (IPF) patients, was found safe and well-tolerated in healthy volunteers participating in a Phase 1 trial, the company announced. Additionally, treatment with the LOXL2 inhibitor, called…
Treatment with Esbriet (pirfenidone) can effectively benefit patients with idiopathic pulmonary fibrosis (IPF) who have more advanced lung function impairment, by preventing a decline in exercise capacity and worsening of shortness of breath (dyspnea). Those findings, taken from additional analysis of Phase 3 clinical trial data, were discussed…
Half a year has gone by since disgraced pharma executive Martin Shkreli was sentenced to seven years in federal prison for securities and wire fraud while heading San Diego-based Retrophin. As founder and CEO of another company (then known as Turing Pharmaceuticals), in late 2015 Shkreli bought the rights…
Ofev, an approved therapy for idiopathic pulmonary fibrosis (IPF), can prevent the progression of squamous cell carcinoma in the lungs associated with IPF, a case study reports. The study, “Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis” was published in the journal…
Studies supporting an investigational new drug (IND) application for X-165, a potential candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders, have been completed, X-Rx recently announced. According to the U.S. Food and Drug Administration, an IND application permits the manufacturer to transport…
Combining Ofev (nintedanib, marketed by Boehringer Ingelheim) with sildenafil does not offer additional clinical benefits when compared to Ofev treatment alone regarding quality of life and lung function in patients with idiopathic…
Veracyte will present new results that showcase the ability of the Envisia Genomic Classifier to provide reliable data that helps physicians diagnose interstitial lung disease (ILD) — including idiopathic pulmonary fibrosis (IPF) — at CHEST 2018 meeting. Veracyte also will present new results about the capability of the…
A recent study in mice shows that endometrial regenerative cells (ERCs) can ease some of the common symptoms of idiopathic pulmonary fibrosis (IPF). Titled “Human Endometrial Regenerative Cells Attenuate Bleomycin-Induced Pulmonary Fibrosis in Mice,” the study was recently published in the journal Stem Cells International. Therapeutic…
Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a real-life clinical setting, an Italian study reported. The study, “Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre” was published in the journal…
Samumed and United Therapeutics announced an exclusive license agreement for North American rights to Samumed’s investigational therapy SM04646 to treat idiopathic pulmonary fibrosis (IPF). Under the agreement, United Therapeutics will pay Samumed $10 million up-front, plus up to $340 million in developmental milestones in addition to other…
Get regular updates to your inbox.
